SlowBull
The Business Brief SATURDAY, 8 AUGUST 2026
← All stories
Deals

Latigo IPO raises nearly $350M for pain drug development

1 source ·1 article ·12h ago

The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·12h ago

Latigo IPO raises nearly $350M for pain drug development

The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.